Last updated: August 5, 2026
Amlodipine besylate/benazepril hydrochloride is an established fixed-dose antihypertensive combination marketed in the United States as Lotrel and multiple generic products. Its commercial opportunity is primarily in low-cost generic supply, manufacturing efficiency, excipient substitution, dose-combination availability, and differentiated adherence products rather than in composition-of-matter exclusivity.
The product is an oral hard-gelatin capsule containing two active pharmaceutical ingredients: the calcium-channel blocker amlodipine besylate and the angiotensin-converting enzyme inhibitor benazepril hydrochloride. FDA-approved strengths include 2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg, and 10 mg/20 mg, expressed as amlodipine equivalent and benazepril hydrochloride, respectively.[1][2]
What is the FDA and commercial status of amlodipine/benazepril?
Amlodipine/benazepril is an approved immediate-release oral fixed-dose combination. The reference product is Lotrel, originally developed by Novartis. Generic products are approved through abbreviated new drug applications under the FDA’s ANDA pathway.[1][3]
| Attribute |
Product information |
| Active ingredients |
Amlodipine besylate and benazepril hydrochloride |
| Drug class |
Calcium-channel blocker plus ACE inhibitor |
| Dosage form |
Immediate-release oral capsule |
| Reference product |
Lotrel |
| FDA pathway for generics |
ANDA |
| U.S. dosage strengths |
2.5/10 mg, 5/10 mg, 5/20 mg, 10/20 mg |
| Primary use |
Hypertension |
| Biosimilar pathway |
Not applicable; both APIs are small molecules |
| Current exclusivity profile |
No meaningful regulatory exclusivity expected for the mature reference product |
| Orange Book relevance |
Product-specific patent and exclusivity listings should be checked by NDA and current edition |
The therapeutic rationale is complementary blood-pressure control. Amlodipine produces vasodilation through calcium-channel blockade, while benazepril suppresses the renin-angiotensin system. The combination can reduce pill burden for patients who require both mechanisms.
The reference product and generic versions do not have the same excipient composition. ANDA applicants must demonstrate pharmaceutical equivalence and bioequivalence, but they generally may use different inactive ingredients when the formulation remains acceptable under FDA requirements.[3]
What excipients are used in amlodipine/benazepril capsules?
The reference formulation uses conventional capsule excipients associated with powder blending, flow improvement, disintegration, lubrication, and capsule-shell manufacture. Public labeling identifies excipient categories that may include lactose monohydrate, microcrystalline cellulose, pregelatinized starch, crospovidone, colloidal silicon dioxide, magnesium stearate, talc, and capsule-shell materials, depending on strength and product presentation.[1][2]
A representative excipient architecture is:
| Formulation function |
Common excipient options |
Commercial purpose |
| Dilution and bulk |
Lactose monohydrate, microcrystalline cellulose, mannitol |
Controls fill weight and blend uniformity |
| Disintegration |
Crospovidone, croscarmellose sodium, sodium starch glycolate |
Supports rapid capsule-plug breakup |
| Flow enhancement |
Colloidal silicon dioxide |
Improves powder flow and dosing consistency |
| Lubrication |
Magnesium stearate, sodium stearyl fumarate |
Reduces adhesion during encapsulation |
| Moisture and process control |
Low-moisture grades of lactose or cellulose |
Limits degradation and variability |
| Capsule shell |
Gelatin, titanium dioxide, permitted colorants |
Provides identification and protection |
| Taste and handling |
Opaque shell, printed capsule |
Improves patient acceptability and product differentiation |
The formulation challenge is not simply to mix two APIs. Amlodipine besylate and benazepril hydrochloride have different physicochemical properties, dose ratios, particle-size behavior, and potential sensitivity to process conditions. Benazepril hydrochloride is an ester-containing prodrug salt and requires control of moisture, heat, and hydrolytic stress. Amlodipine besylate is present at a comparatively low dose in several strengths, which makes content uniformity and segregation control important.
How should manufacturers design the excipient platform?
A robust platform should use a common blend architecture across strengths wherever possible. The manufacturer can change API quantities while maintaining a controlled total fill weight through a calibrated filler system. This reduces tooling changes, validation burden, and inventory complexity.
Blend uniformity and segregation control
The 2.5 mg amlodipine strength presents the highest relative content-uniformity risk. The formulation should use:
- Controlled API particle-size distributions.
- Geometric dilution or ordered blending for low-dose amlodipine.
- A filler with a compatible density and particle-size distribution.
- Low-shear transfer and minimized hopper residence time.
- In-process blend sampling supported by statistically justified sampling plans.
Microcrystalline cellulose can improve compaction and powder handling, but excessive fibrous material may impair flow in some encapsulation systems. Lactose offers cost efficiency and good blending performance, although moisture specification and compatibility assessment are important. Mannitol may support a lower-lactose or premium positioning but typically carries a higher material cost.
Disintegration strategy
Because the product is an immediate-release capsule, disintegration rather than tablet hardness is the primary performance concern. Crospovidone is attractive where rapid capillary action and low gelling risk are priorities. Croscarmellose sodium and sodium starch glycolate offer alternative performance profiles but can behave differently with moisture and compression-independent capsule plugs.
The formulation target should be rapid and reproducible drug release across physiological pH conditions. Dissolution development should assess each strength separately because the API-to-excipient ratio changes across the product line.
Lubrication and over-lubrication risk
Magnesium stearate is widely available and inexpensive. Excessive concentration or blending time can reduce wetting and slow dissolution. Sodium stearyl fumarate may be considered where a less hydrophobic lubrication system is commercially justified, but the change requires comparative dissolution and bioequivalence assessment.
Capsule-shell selection
Hard-gelatin capsules are the lowest-risk platform because they align with the established dosage form. Hydroxypropyl methylcellulose capsules may provide a vegetarian, lower-moisture, or premium alternative. The switch can affect shell dissolution, moisture transfer, machine performance, printing, and packaging stability.
A capsule-shell change is commercially useful only if it creates a measurable advantage, such as improved supply continuity, vegetarian positioning, reduced shell brittleness, or better performance in humidity-controlled markets.
What formulation patents protect amlodipine/benazepril?
The principal commercial barriers are no longer expected to arise from the original active-ingredient patents. Amlodipine and benazepril are mature small molecules, and the core combination has been subject to generic competition for many years.
Relevant protection historically could include:
- Composition claims covering the fixed-dose combination.
- Capsule formulations.
- Salt and polymorph claims.
- Manufacturing processes.
- Stability-enhancing excipient systems.
- Method-of-use claims for hypertension treatment.
For a current U.S. product assessment, the controlling source is the FDA Orange Book record for Lotrel and approved abbreviated applications. Patent status can change through listing corrections, delistings, pediatric exclusivity events, or litigation outcomes. A current Orange Book review is required before relying on a specific patent-expiration date.[3]
The practical conclusion is that a new generic manufacturer is unlikely to face a meaningful barrier from the basic combination itself. Risk is more likely to arise from regulatory deficiencies, bioequivalence failure, supply reliability, or an unrecognized formulation or method-of-use listing than from an active blocking patent estate.
When does amlodipine/benazepril lose exclusivity?
The product has already passed its meaningful U.S. market exclusivity period. The commercial market is mature and supports multiple generic entrants. FDA approval of a generic depends on the ANDA applicant meeting requirements for pharmaceutical equivalence, bioequivalence, chemistry, manufacturing and controls, labeling, and facility compliance.[3][4]
| Exclusivity category |
Assessment |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Biosimilar reference exclusivity |
Not applicable |
| Pediatric exclusivity |
Any historical period would be expired |
| Formulation exclusivity |
No broad current barrier apparent from the mature product profile |
| Generic competition |
Established |
The absence of current exclusivity does not eliminate regulatory risk. A product can remain commercially difficult if the market has low prices, limited volume, concentrated wholesalers, or inconsistent API supply.
What generic entry risks exist?
Generic launch risk is moderate from a technical perspective and high from a margin perspective.
Technical risks
The principal technical risks are:
- Low-dose amlodipine uniformity. The 2.5 mg strength requires tight control of blend homogeneity.
- API segregation. Differences in density, particle size, and electrostatic behavior can produce capsule-to-capsule variability.
- Moisture-driven degradation. Benazepril hydrochloride should be evaluated under accelerated and long-term stability conditions with appropriate degradation-product monitoring.
- Dissolution mismatch. A different filler, disintegrant, or lubricant system can alter release performance.
- Capsule-shell variability. Shell moisture, brittleness, and dissolution can affect manufacture and stability.
- Packaging performance. Bottles, desiccants, induction seals, and blister systems can materially change moisture protection.
Commercial risks
The product has several structural commercial risks:
- Low generic pricing after multiple approvals.
- Limited ability to differentiate through therapeutic claims.
- Commodity-level competition among contract manufacturers.
- Retail substitution away from the reference brand.
- Inventory pressure from four strengths.
- Potentially small market share per additional entrant.
A manufacturer should avoid launching all strengths unless demand, contract access, and supply economics justify the additional inventory and validation burden.
What commercial opportunities exist in excipients?
The strongest opportunities are in cost reduction, supply resilience, and differentiated capsule platforms.
Low-cost generic platform
A lactose/microcrystalline-cellulose filler system with crospovidone, colloidal silicon dioxide, and magnesium stearate is likely to offer the lowest manufacturing complexity. The opportunity is suitable for high-volume generic suppliers competing on price and reliable fill rates.
Lactose-free or low-lactose product
A mannitol, microcrystalline cellulose, or dibasic calcium phosphate platform could support a lactose-free positioning. This may help procurement in certain markets, although the commercial value is limited because the product is a prescription generic and physicians rarely select it by excipient profile.
Vegetarian capsule platform
Hydroxypropyl methylcellulose shells can support a vegetarian or religious-compliance claim where permitted. The value is greater in selected international markets, private-label channels, and institutional tenders than in standard U.S. generic substitution.
Moisture-control platform
A moisture-optimized excipient system, high-barrier blister, or desiccant bottle can reduce stability risk and improve distribution in hot and humid regions. This is a practical opportunity for manufacturers supplying emerging markets or operating with long distribution chains.
Pediatric and swallowing-oriented formats
Amlodipine/benazepril is primarily an adult hypertension product, and a new pediatric formulation would require clinical, dosing, and regulatory work. A sprinkle capsule, dispersible multiparticulate product, or oral suspension could create differentiation, but it would likely require more than an excipient substitution. Dose flexibility and stability would be central development issues.
Combination-product adherence packaging
Calendar blister packs, synchronized refill programs, and combination-dose starter packs can improve adherence without changing the drug formulation. The commercial opportunity is greater than for minor excipient changes because the value proposition is operational and patient-facing.
How does the patent estate compare with competing antihypertensive combinations?
Amlodipine/benazepril has a weaker exclusivity profile than newer branded combinations and a more commoditized market position than recently launched cardiovascular products. Its advantage is established clinical use and manufacturing familiarity.
| Product category |
Patent and exclusivity profile |
Excipient opportunity |
| Amlodipine/benazepril |
Mature, genericized fixed-dose combination |
Cost, stability, capsule platform |
| Amlodipine/valsartan |
Mature combination with broad generic competition |
Dose-line extensions and adherence packaging |
| Amlodipine/losartan |
Mature generic combination |
Similar commodity formulation opportunities |
| ACE inhibitor/thiazide combinations |
Mature generic category |
Tablet process efficiency and low-cost excipients |
| Newer branded cardiovascular combinations |
Potentially active patents or exclusivity |
Higher-value differentiated delivery systems |
The product is therefore better viewed as a platform for operational excellence than as an asset with meaningful patent leverage.
What is the litigation and Paragraph IV outlook?
Paragraph IV litigation risk is generally lower for a mature combination with extensive generic presence than for a newly approved product. A new ANDA applicant could still trigger litigation if the Orange Book contains an unexpired patent certification requirement. The applicant would need to evaluate each listed patent, claim scope, expiration date, pediatric extensions, and any settlement terms before filing.
No reliable commercial conclusion should be drawn from the absence of widely reported recent litigation alone. Patent listings and docket activity must be reviewed at the time of filing. Settlement agreements can include delayed-entry dates, authorized-generic provisions, or restrictions tied to specific strengths and formulations.
For an excipient supplier, litigation exposure is usually indirect. The key risk is whether the excipient system is incorporated into a formulation that implicates a listed formulation patent. A supplier should support freedom-to-operate analysis with ingredient specifications, formulation-development records, and clear separation between functional excipient selection and patented claim elements.
Which manufacturing and IP barriers matter most?
The most important barriers are process and quality barriers rather than basic patent barriers.
Manufacturers should control:
- API particle-size and polymorph specifications.
- Blend uniformity for low-dose amlodipine.
- Benazepril degradation products.
- Capsule fill-weight variation.
- Dissolution across all strengths.
- Moisture ingress during packaging and storage.
- Supplier qualification for both APIs and critical excipients.
- Change-control procedures for excipient grade substitutions.
Geographic protection is also relevant. U.S., European, Canadian, Latin American, and Asian markets may have different registered strengths, capsule colors, excipient restrictions, labeling requirements, and patent records. A formulation approved in the United States may require separate stability, excipient, or bioequivalence analysis in another jurisdiction.
Key Takeaways
- Amlodipine/benazepril is a mature generic fixed-dose combination with limited current exclusivity value.
- The relevant U.S. dosage forms are immediate-release hard-gelatin capsules in four principal strength combinations.
- The highest technical risk is content uniformity of low-dose amlodipine, followed by moisture and degradation control for benazepril hydrochloride.
- Conventional excipients provide the lowest-cost route, while lactose-free shells, HPMC capsules, moisture-resistant packaging, and adherence systems offer selective differentiation.
- Formulation patents should be checked against the current Orange Book record before launch, but the core product is unlikely to present a broad blocking patent barrier.
- Commercial returns depend more on manufacturing cost, supply reliability, wholesaler access, and strength coverage than on premium pricing.
- A new entrant should prioritize a common excipient platform, strong blend-control data, and packaging that protects against humidity.
FAQs
Can amlodipine/benazepril be formulated as a tablet instead of a capsule?
Yes, but a tablet would be a different dosage-form strategy and would require development, dissolution, stability, and bioequivalence support. The established reference product is a capsule.
Which excipient is most important for the 2.5 mg amlodipine strength?
The blend-dilution and uniformity system is most important. Filler selection, API particle size, geometric dilution, and segregation control determine whether the low-dose capsule meets content-uniformity requirements.
Is benazepril hydrochloride compatible with lactose?
Compatibility must be demonstrated through formulation and stability studies. Lactose is widely used in oral pharmaceuticals, but the specific API, water activity, processing conditions, and degradation profile determine suitability.
Can an HPMC capsule create patent differentiation?
An HPMC shell may create a product distinction, but it does not automatically avoid a formulation patent. Claim scope must be compared with the full composition and dosage-form design.
Is a new fixed-dose combination likely to obtain premium pricing?
Not in the standard U.S. generic channel. Premium potential would require a differentiated product, such as improved dose flexibility, moisture robustness, adherence packaging, or a clinically supported alternative administration format.
References
-
DailyMed. (n.d.). Lotrel: Amlodipine besylate and benazepril hydrochloride capsule, prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
Novartis Pharmaceuticals Corporation. (n.d.). Lotrel prescribing information. U.S. Food and Drug Administration labeling archive.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2019). Guidance for industry: ANDAs for certain highly purified synthetic peptides. U.S. Department of Health and Human Services. https://www.fda.gov/ рег
